Important note: Information in this article was accurate in 2007. The state of the art may have changed since the publication date.
 |
San Francisco Examiner - August 1, 2007
Len Lazarick, llazarick@baltimoreexaminer.com
But Dr. Robert Gallo, who heads the Institute of Human Virology at the University of Maryland School of Medicine and who co-discovered the HIV virus that causes AIDS, said the worst thing that could happen is a headline that says: "We have a vaccine for AIDS. That's not the case."
"We have a vaccine candidate that is extra interesting and certainly unique in its properties," Gallo told a State House news conference announcing the grant.
AIDS has fallen off the front pages in recent years, but it kills 250,000 a month worldwide, "a tsunami a month," Gallo said, compared with the 200,000 who died in the Asian tsunami of 2004.
This grant is for both basic research and development of an AIDS vaccine, said Dave Wilkins, chief operating officer of the Institute of Human Virology.
For two decades, Gallo has been a world-renowned figure in AIDS research - he developed the first blood test for HIV. He wowed a room of state officials and reporters with a short course on AIDS and the failed attempts to find a vaccine against the deadly killer that destroys the body's immune system.
Early attempts to immunize people against the HIV virus by using the live virus or killing the virus, as vaccines for other diseases do, were not successful, Gallo said.
"You're left with two hands tied behind you're back, but we still have our teeth and our feet," Gallo said.
The problem with HIV is that it constantly adapts to different forms in the body.
With AIDS, "when you get infected, you're infected forever," Gallo said.
The most promising results involve preventing the connectors on the outside of the virus from attaching themselves to cells, Gallo said. The new vaccine is far enough along that the technology has been licensed by Wyeth Pharmaceuticals through the institute's commercial arm, Profectus BioSciences.
Gallo said they are hoping for positive results from clinical tests on monkeys early next year.
070801
SE070805
Copyright © 2007 - San Francisco Examiner. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the San Francisco Examiner, Permissions Desk, 110 Fifth Street, P.O. Box 7260, San Franciso, CA 94120.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, the National Library of Medicine, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 2007. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2007. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .